Dataset Information

The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database.

ABSTRACT: At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are high, and experts foresee that AI/ML shows potential for diagnosing, managing and treating a wide variety of medical conditions. However, the obstacles for implementation of AI/ML in daily clinical practice are numerous, especially regarding the regulation of these technologies. Therefore, we provide an insight into the currently available AI/ML-based medical devices and algorithms that have been approved by the US Food & Drugs Administration (FDA). We aimed to raise awareness of the importance of regulatory bodies, clearly stating whether a medical device is AI/ML based or not. Cross-checking and validating all approvals, we identified 64 AI/ML based, FDA approved medical devices and algorithms. Out of those, only 29 (45%) mentioned any AI/ML-related expressions in the official FDA announcement. The majority (85.9%) was approved by the FDA with a 510(k) clearance, while 8 (12.5%) received de novo pathway clearance and one (1.6%) premarket approval (PMA) clearance. Most of these technologies, notably 30 (46.9%), 16 (25.0%), and 10 (15.6%) were developed for the fields of Radiology, Cardiology and Internal Medicine/General Practice respectively. We have launched the first comprehensive and open access database of strictly AI/ML-based medical technologies that have been approved by the FDA. The database will be constantly updated.

SUBMITTER: Benjamens S

PROVIDER: S-EPMC7486909 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ObjectiveTo determine the rigor, generalizability, and reproducibility of published classification and detection artificial intelligence (AI) models for prostate cancer (PCa) on MRI using the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) guidelines, a 42-item checklist that is considered a measure of best practice for presenting and reviewing medical imaging AI research.Materials and methodsThis review searched English literature for studies proposing PCa AI detection and classification models on MRI. Each study was evaluated with the CLAIM checklist. The additional outcomes for which data were sought included measures of AI model performance (eg, area under the curve [AUC], sensitivity, specificity, free-response operating characteristic curves), training and validation and testing group sample size, AI approach, detection versus classification AI, public data set utilization, MRI sequences used, and definition of gold standard for ground truth. The percentage of CLAIM checklist fulfillment was used to stratify studies into quartiles. Wilcoxon's rank-sum test was used for pair-wise comparisons.ResultsIn all, 75 studies were identified, and 53 studies qualified for analysis. The original CLAIM items that most studies did not fulfill includes item 12 (77% no): de-identification methods; item 13 (68% no): handling missing data; item 15 (47% no): rationale for choosing ground truth reference standard; item 18 (55% no): measurements of inter- and intrareader variability; item 31 (60% no): inclusion of validated interpretability maps; item 37 (92% no): inclusion of failure analysis to elucidate AI model weaknesses. An AUC score versus percentage CLAIM fulfillment quartile revealed a significant difference of the mean AUC scores between quartile 1 versus quartile 2 (0.78 versus 0.86, P = .034) and quartile 1 versus quartile 4 (0.78 versus 0.89, P = .003) scores. Based on additional information and outcome metrics gathered in this study, additional measures of best practice are defined. These new items include disclosure of public dataset usage, ground truth definition in comparison to other referenced works in the defined task, and sample size power calculation.ConclusionA large proportion of AI studies do not fulfill key items in CLAIM guidelines within their methods and results sections. The percentage of CLAIM checklist fulfillment is weakly associated with improved AI model performance. Additions or supplementations to CLAIM are recommended to improve publishing standards and aid reviewers in determining study rigor.

Project description:Natural Language Processing (NLP) is a subset of artificial intelligence that enables machines to understand and respond to human language through Large Language Models (LLMs)‥ These models have diverse applications in fields such as medical research, scientific writing, and publishing, but concerns such as hallucination, ethical issues, bias, and cybersecurity need to be addressed. To understand the scientific community's understanding and perspective on the role of Artificial Intelligence (AI) in research and authorship, a survey was designed for corresponding authors in top medical journals. An online survey was conducted from July 13th, 2023, to September 1st, 2023, using the SurveyMonkey web instrument, and the population of interest were corresponding authors who published in 2022 in the 15 highest-impact medical journals, as ranked by the Journal Citation Report. The survey link has been sent to all the identified corresponding authors by mail. A total of 266 authors answered, and 236 entered the final analysis. Most of the researchers (40.6%) reported having moderate familiarity with artificial intelligence, while a minority (4.4%) had no associated knowledge. Furthermore, the vast majority (79.0%) believe that artificial intelligence will play a major role in the future of research. Of note, no correlation between academic metrics and artificial intelligence knowledge or confidence was found. The results indicate that although researchers have varying degrees of familiarity with artificial intelligence, its use in scientific research is still in its early phases. Despite lacking formal AI training, many scholars publishing in high-impact journals have started integrating such technologies into their projects, including rephrasing, translation, and proofreading tasks. Efforts should focus on providing training for their effective use, establishing guidelines by journal editors, and creating software applications that bundle multiple integrated tools into a single platform.

Project description:The transdermal route of drug administration has gained popularity for its convenience and bypassing the first-pass metabolism. Accurate skin permeability prediction is crucial for successful transdermal drug delivery (TDD). In this study, we address this critical need to enhance TDD. A dataset comprising 441 records for 140 molecules with diverse LogKp values was characterized. The descriptor calculation yielded 145 relevant descriptors. Machine learning models, including MLR, RF, XGBoost, CatBoost, LGBM, and ANN, were employed for regression analysis. Notably, LGBM, XGBoost, and gradient boosting models outperformed others, demonstrating superior predictive accuracy. Key descriptors influencing skin permeability, such as hydrophobicity, hydrogen bond donors, hydrogen bond acceptors, and topological polar surface area, were identified and visualized. Cluster analysis applied to the FDA-approved drug dataset (2326 compounds) revealed four distinct clusters with significant differences in molecular characteristics. Predicted LogKp values for these clusters offered insights into the permeability variations among FDA-approved drugs. Furthermore, an investigation into skin permeability patterns across 83 classes of FDA-approved drugs based on the ATC code showcased significant differences, providing valuable information for drug development strategies. The study underscores the importance of accurate skin permeability prediction for TDD, emphasizing the superior performance of nonlinear machine learning models. The identified key descriptors and clusters contribute to a nuanced understanding of permeability characteristics among FDA-approved drugs. These findings offer actionable insights for drug design, formulation, and prioritization of molecules with optimum properties, potentially reducing reliance on costly experimental testing. Future research directions include offering promising applications in pharmaceutical research and formulation within the burgeoning field of computer-aided drug design.

Dataset Information

The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets